Medicine Description stalveo 37.5mg
Stalveo 37.5 mg 30 tablets is a medication that combines carbidopa, entacapone, and levodopa to effectively manage the symptoms of Parkinson's disease. Levodopa is a precursor to dopamine which, once converted in the brain, helps replenish the deficiency of this crucial neurotransmitter. Carbidopa is included to inhibit the peripheral conversion of levodopa to dopamine, ensuring that more levodopa reaches the brain. Entacapone acts as a catechol-O-methyltransferase (COMT) inhibitor, enhancing and prolonging the effect of levodopa by preventing its breakdown. Together, this synergistic action maintains higher dopamine levels in the brain, which is essential for regulating movement and alleviating the motor symptoms characteristic of Parkinson's disease.
Indications and Uses of Stalveo 37.5 mg 30 tablets
- Treatment of motor symptoms in patients with Parkinson's disease.
- Management of 'off periods' in patients already on a stable dose of levodopa.
Side Effects of Stalveo 37.5 mg 30 tablets
- Nausea
- Dizziness
- Fatigue
- Orthostatic hypotension
- Dry mouth
- Hallucinations
Storage and Handling
Store Stalveo tablets at room temperature, away from moisture and heat. Keep the medication out of reach of children and do not use after the expiration date.
Patient Advice and Precautions
Patients should be regularly monitored by healthcare professionals to assess the effectiveness of the treatment and adjust as necessary. Inform your doctor of any side effects experienced, especially if they are severe or persistent. Avoid sudden discontinuation of the medication as it may lead to withdrawal symptoms. Maintain hydration and consider dietary adjustments to help manage gastrointestinal side effects.